JP4127325B2 - ビオチン誘導体 - Google Patents

ビオチン誘導体 Download PDF

Info

Publication number
JP4127325B2
JP4127325B2 JP26372696A JP26372696A JP4127325B2 JP 4127325 B2 JP4127325 B2 JP 4127325B2 JP 26372696 A JP26372696 A JP 26372696A JP 26372696 A JP26372696 A JP 26372696A JP 4127325 B2 JP4127325 B2 JP 4127325B2
Authority
JP
Japan
Prior art keywords
phe
lys
asp
tyr
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP26372696A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09124692A (ja
JPH09124692A5 (OSRAM
Inventor
アルフレート・ヨンツィク
サイモン・グッドマン
ベーテ・ディーフェンバッハ
ホルスト・ケスラー
ディルク・フィンジンガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JPH09124692A publication Critical patent/JPH09124692A/ja
Publication of JPH09124692A5 publication Critical patent/JPH09124692A5/ja
Application granted granted Critical
Publication of JP4127325B2 publication Critical patent/JP4127325B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
JP26372696A 1995-09-14 1996-09-13 ビオチン誘導体 Expired - Fee Related JP4127325B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19534016.7 1995-09-14
DE19534016A DE19534016A1 (de) 1995-09-14 1995-09-14 Biotinderivate

Publications (3)

Publication Number Publication Date
JPH09124692A JPH09124692A (ja) 1997-05-13
JPH09124692A5 JPH09124692A5 (OSRAM) 2004-09-30
JP4127325B2 true JP4127325B2 (ja) 2008-07-30

Family

ID=7772112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26372696A Expired - Fee Related JP4127325B2 (ja) 1995-09-14 1996-09-13 ビオチン誘導体

Country Status (23)

Country Link
EP (1) EP0771818B1 (OSRAM)
JP (1) JP4127325B2 (OSRAM)
KR (1) KR970015597A (OSRAM)
CN (1) CN1168738C (OSRAM)
AT (1) ATE215558T1 (OSRAM)
AU (1) AU719307B2 (OSRAM)
BR (1) BR9603741A (OSRAM)
CA (1) CA2185394C (OSRAM)
CZ (1) CZ291506B6 (OSRAM)
DE (2) DE19534016A1 (OSRAM)
DK (1) DK0771818T3 (OSRAM)
ES (1) ES2174007T3 (OSRAM)
HU (1) HUP9602223A3 (OSRAM)
MX (1) MX9604019A (OSRAM)
NO (1) NO314694B1 (OSRAM)
PL (1) PL316069A1 (OSRAM)
PT (1) PT771818E (OSRAM)
RU (1) RU2171807C2 (OSRAM)
SI (1) SI0771818T1 (OSRAM)
SK (1) SK283129B6 (OSRAM)
TW (1) TW517063B (OSRAM)
UA (1) UA41981C2 (OSRAM)
ZA (1) ZA967765B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1398189A (zh) 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
EP1257566A4 (en) * 2000-02-11 2005-06-15 Univ Duke METHOD OF TREATING EYE PATHOLOGIES
KR100778633B1 (ko) * 2007-04-13 2007-11-28 성균관대학교산학협력단 비오틴과 비오틴-폴리에틸렌글리콜이 접합된 ｇｌｐ-1유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
CN101990425B (zh) * 2008-04-08 2016-01-20 默克专利股份有限公司 包含环肽的组合物和使用方法
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用
CN113827591B (zh) * 2021-11-09 2023-06-09 上海市肺科医院 生物素在制备治疗脓毒症药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315076B2 (OSRAM) * 1973-09-27 1978-05-22
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
US6287792B1 (en) * 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE4336758A1 (de) * 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren

Also Published As

Publication number Publication date
PT771818E (pt) 2002-09-30
HU9602223D0 (en) 1996-10-28
JPH09124692A (ja) 1997-05-13
EP0771818A3 (de) 1997-07-02
UA41981C2 (uk) 2001-10-15
TW517063B (en) 2003-01-11
CN1168738C (zh) 2004-09-29
CA2185394C (en) 2007-05-01
NO963851D0 (no) 1996-09-13
SI0771818T1 (en) 2002-10-31
EP0771818B1 (de) 2002-04-03
EP0771818A2 (de) 1997-05-07
HUP9602223A3 (en) 1998-03-02
SK115696A3 (en) 1997-05-07
RU2171807C2 (ru) 2001-08-10
MX9604019A (es) 1997-03-29
DE59608995D1 (de) 2002-05-08
BR9603741A (pt) 1998-06-02
DK0771818T3 (da) 2002-07-29
CA2185394A1 (en) 1997-03-15
ATE215558T1 (de) 2002-04-15
DE19534016A1 (de) 1997-03-20
KR970015597A (ko) 1997-04-28
AU719307B2 (en) 2000-05-04
HUP9602223A2 (en) 1997-06-30
ES2174007T3 (es) 2002-11-01
NO314694B1 (no) 2003-05-05
CN1153784A (zh) 1997-07-09
CZ291506B6 (cs) 2003-03-12
NO963851L (no) 1997-03-17
ZA967765B (en) 1997-03-26
CZ262996A3 (cs) 1998-02-18
PL316069A1 (en) 1997-03-17
SK283129B6 (sk) 2003-02-04
AU6551896A (en) 1997-03-20

Similar Documents

Publication Publication Date Title
KR100304201B1 (ko) 환상의부착저해제
JP4116062B2 (ja) 環状接着阻害剤
EP0578728B1 (en) PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa
MXPA96004100A (en) Cyclic compounds, adhes inhibitors
US6127335A (en) Cyclic adhesion inhibitors
JPH07304795A (ja) 一般式ｉのシクロペプチド
KR20020010928A (ko) 인테그린 αｖβ６의 억제제로서의 사이클릭 펩타이드유도체
JPH06321988A (ja) 新規直鎖状ペプチド
CZ288379B6 (en) Cyclopeptide derivative, process of its preparation and pharmaceutical preparations in which it is comprised
RU2188205C2 (ru) Циклические азапептиды с ангиогенным действием
AU719307B2 (en) Biotin derivatives
AU690923B2 (en) Linear adhesion inhibitors
CZ20014484A3 (cs) Inhibitory integrinu alfa v beta 6

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080408

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080507

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110523

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110523

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120523

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130523

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130523

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees